Investor Presentaiton

13 Any-Line MUM and Hepatic-Only MUM Clinical Efficacy Clinical Efficacy irrespective of HLA-A2 Status and in Hepatic & Extra-Hepatic Metastases 60% 50% 40% 30% Darovasertib + Crizotinib Phase 2 Any-Line MUM (n=63) Confirmed 30% ORR and 87% DCR Response by RECIST 1.1 Any-Line MUM Best Tumor Response (%) Best Tumor Response (%) 20% 10% 0% -10% -20% -30% -40% -50% First Line Patients Pretreated Patients -60% -70% Heavily pretreated with 68% having >1 prior line and 43% with >2 prior lines of therapy in metastatic setting -80% 40% 30% 20% 10% 0% -10% -20% -30% -40% -50% -60% -70% -80% Evaluable (N=63) 30% PD Confirmed ORR (19/63) 92% Tumor Shrinkage (58/63) SD 41% >30% Tumor Shrinkage (26/63) Best Overall Response PR CPR (19/63) + + +++++ ++ uPR (4/63) + + + SD (32/63) + Confirmed Partial Response +++ 30% 6% 51% 87% DCR (55/63) Darovasertib + Crizotinib Phase 2 Hepatic-Only MUM (n= 20) + + + + + + Confirmed Partial Response + Confirmed 35% ORR and 100% DCR Response by RECIST 1.1 Evaluable PD in Hepatic-Only MUM (N=20) Confirmed ORR (7/20) 35% SD Tumor Shrinkage (20/20) 100% >30% Tumor Shrinkage (9/20) 45% PR Best Overall Response CPR (7/20) UPR (1/20) SD (12/20) DCR (20/20) 35% 5% 60% 100% IDEAYA Data: preliminary analysis of unlocked database as of 03/08/2023 by investigator review, C1D1 cutoff as of 9/22/2022, based on 63 evaluable Any-Line and 20 evaluable Hepatic-Only (includes 1L and 2L+/pre-treated) MUM patients ORR = Overall Response Rate; DCR = Disease Control Rate; CPR = Confirmed Partial Response; uPR = Unconfirmed Partial Response; SD = Stable Disease IDEA A BIOSCIENCES

View entire presentation